Mexiletine for Myotonia: A New Use for an Old Heart Drug?

A generic cardiovascular drug called mexiletine, initially developed to treat heart rhythm abnormalities, appears to hold some potential for treating muscle stiffness and other symptoms of non-dystrophic myotonias (NDMs),

Dysregulation of Circular RNAs in DM1

Circular RNAs that play a role in myogenesis are dysregulated in DM1 skeletal muscle.

What is the Actual Progenitor Allele Length in Any Given DM1 Patient?

A new study examines approaches to determine DM1 study subject progenitor allele length.

Targeting DM1 with a Multivalent Ligand

Multivalent ligands show bioavailability and efficacy in targeting splicing defects in DM1.

Antisense Oligonucleotides Make Sense in Myotonic Dystrophy

Antisense oligonucleotides – short segments of genetic material designed to target specific areas of a gene

Scientists Create Potent Molecules Aimed at Treating Myotonic Dystrophy

The new approach could have implications for many genetic diseases.

MDF Awards $400,000 for Research into Treatments for Myotonic Dystrophy

ROSEVILLE, CA (January 25, 2012): MDF is pleased to announce its largest-ever round of Fund-A-Fellow postdoctoral fellowship research grant awards.

© Myotonic Dystrophy Foundation. All rights reserved.